AR078863A1 - Derivados de espiropiperidina antagonista de receptores orl-1, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de la migrana, obesidad y/o depresion. - Google Patents

Derivados de espiropiperidina antagonista de receptores orl-1, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de la migrana, obesidad y/o depresion.

Info

Publication number
AR078863A1
AR078863A1 ARP100104035A ARP100104035A AR078863A1 AR 078863 A1 AR078863 A1 AR 078863A1 AR P100104035 A ARP100104035 A AR P100104035A AR P100104035 A ARP100104035 A AR P100104035A AR 078863 A1 AR078863 A1 AR 078863A1
Authority
AR
Argentina
Prior art keywords
ylmethyl
hydrogen
obesity
depression
treatment
Prior art date
Application number
ARP100104035A
Other languages
English (en)
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR078863A1 publication Critical patent/AR078863A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP100104035A 2009-11-16 2010-11-02 Derivados de espiropiperidina antagonista de receptores orl-1, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de la migrana, obesidad y/o depresion. AR078863A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382246 2009-11-16
US29862910P 2010-01-27 2010-01-27

Publications (1)

Publication Number Publication Date
AR078863A1 true AR078863A1 (es) 2011-12-07

Family

ID=41728051

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104035A AR078863A1 (es) 2009-11-16 2010-11-02 Derivados de espiropiperidina antagonista de receptores orl-1, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de la migrana, obesidad y/o depresion.

Country Status (34)

Country Link
US (1) US8232289B2 (https=)
EP (1) EP2501703B1 (https=)
JP (1) JP5680101B2 (https=)
KR (1) KR101363830B1 (https=)
CN (1) CN102612520B (https=)
AR (1) AR078863A1 (https=)
AU (1) AU2010319581C1 (https=)
CA (1) CA2796161C (https=)
CO (1) CO6541545A2 (https=)
CR (1) CR20130087A (https=)
DK (1) DK2501703T3 (https=)
DO (1) DOP2012000135A (https=)
EA (1) EA020848B1 (https=)
EC (1) ECSP12011902A (https=)
ES (1) ES2435814T3 (https=)
HN (1) HN2012001011A (https=)
HR (1) HRP20130967T1 (https=)
IL (1) IL219370A (https=)
JO (1) JO2887B1 (https=)
MA (1) MA33751B1 (https=)
ME (1) ME01537B (https=)
MX (1) MX2012005691A (https=)
MY (1) MY160665A (https=)
NZ (1) NZ600006A (https=)
PE (1) PE20121430A1 (https=)
PH (1) PH12012500969A1 (https=)
PL (1) PL2501703T3 (https=)
PT (1) PT2501703E (https=)
RS (1) RS53018B (https=)
SI (1) SI2501703T1 (https=)
TW (1) TWI465453B (https=)
UA (1) UA107943C2 (https=)
WO (1) WO2011060035A1 (https=)
ZA (1) ZA201202967B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106883246B (zh) * 2009-12-04 2020-05-29 桑诺维恩药品公司 多环化合物及其使用方法
US9394290B2 (en) * 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之４',５'－二氫螺［哌啶－４,７'－噻吩并[２，３－c]哌喃］化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之ｏｒｌ－１受體拮抗劑
CR20190436A (es) 2012-10-02 2019-10-29 Bayer Cropscience Ag COMPUESTOS HETEROCICLICOS COMO PLAGUICIDAS (Divisional 2015-0182)
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
JO3638B1 (ar) * 2015-09-09 2020-08-27 Lilly Co Eli مركبات مفيدة في تثبيط ror - جاما- t
UA125519C2 (uk) 2016-07-29 2022-04-13 Суновіон Фармасьютікалз Інк. Сполуки і композиції і їх застосування
CA3032141A1 (en) 2016-07-29 2018-02-01 Vadim ALEXANDROV Compounds and compositions and uses thereof
IL268694B2 (en) 2017-02-16 2023-10-01 Sunovion Pharmaceuticals Inc Treatment of schizophrenia
DK3589637T3 (da) * 2017-03-02 2021-06-14 Lilly Co Eli Forbindelser, der er anvendelige til inhibering af ROR-GAMMA-T
PL3589638T3 (pl) 2017-03-02 2021-09-27 Eli Lilly And Company Związki użyteczne do hamowania ror-gamma-t
BR112020001433A2 (pt) 2017-08-02 2020-07-28 Sunovion Pharmaceuticals Inc. compostos de isocromano e usos dos mesmos
EA202091945A1 (ru) 2018-02-16 2021-01-18 Суновион Фармасьютикалз Инк. Соли, кристаллические формы и способы их получения
TWI848031B (zh) 2018-12-17 2024-07-11 美商維泰克斯製藥公司 Apol1抑制劑及其使用方法
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
CN115734785A (zh) 2020-04-14 2023-03-03 桑诺维恩药品公司 (S)-(4,5-二氢-7H-噻吩并[2,3-c]吡喃-7-基)-N-甲基甲胺用于治疗神经和精神方面的病症
WO2021252863A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and using the same
IL300298B2 (en) 2020-08-26 2025-06-01 Vertex Pharma Inhibitors of apol1 and methods of using same
CN119343353A (zh) * 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
US6686370B2 (en) * 1999-12-06 2004-02-03 Euro-Celtique S.A. Triazospiro compounds having nociceptin receptor affinity
KR100628292B1 (ko) * 2001-04-18 2006-09-27 유로-셀티크 소시에떼 아노뉨 스파이로파이라졸 화합물
WO2002088089A1 (en) 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Spiropiperidine derivatives, nociceptin receptor antagonists containing the same as the active ingredient and medicinal compositions
WO2003010168A1 (fr) * 2001-07-23 2003-02-06 Banyu Pharmaceutical Co., Ltd. Derive de 4-oxoimidazolidine-2-spiropiperidine
WO2003064425A1 (en) * 2002-01-28 2003-08-07 Pfizer Japan Inc. N-substituted spiropiperidine compounds as ligands for orl-1 receptor
AU2003235912A1 (en) 2002-05-10 2003-11-11 Taisho Pharmaceutical Co., Ltd. Spiro-ring compound
US6995168B2 (en) * 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
NZ538307A (en) * 2002-09-09 2008-04-30 Janssen Pharmaceutica Nv Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
CA2563164A1 (en) * 2004-03-29 2005-10-06 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
AU2009228647B2 (en) * 2008-03-27 2013-07-04 Grunenthal Gmbh Substituted spirocyclic cyclohexane derivatives

Also Published As

Publication number Publication date
US20110118251A1 (en) 2011-05-19
HN2012001011A (es) 2015-08-31
KR101363830B1 (ko) 2014-02-14
RS53018B (sr) 2014-04-30
WO2011060035A1 (en) 2011-05-19
EP2501703B1 (en) 2013-09-18
AU2010319581C1 (en) 2014-05-15
JP2013510859A (ja) 2013-03-28
SI2501703T1 (sl) 2013-11-29
AU2010319581A1 (en) 2012-06-07
NZ600006A (en) 2014-05-30
MY160665A (en) 2017-03-15
CO6541545A2 (es) 2012-10-16
ECSP12011902A (es) 2012-07-31
CR20130087A (es) 2013-04-17
KR20130026523A (ko) 2013-03-13
DOP2012000135A (es) 2012-08-15
EP2501703A1 (en) 2012-09-26
PL2501703T3 (pl) 2014-02-28
IL219370A (en) 2015-01-29
CN102612520A (zh) 2012-07-25
JO2887B1 (en) 2015-03-15
PE20121430A1 (es) 2012-10-26
PH12012500969A1 (en) 2013-01-07
AU2010319581B2 (en) 2013-12-19
ES2435814T3 (es) 2013-12-23
PT2501703E (pt) 2013-11-26
DK2501703T3 (da) 2013-10-14
MA33751B1 (fr) 2012-11-01
ME01537B (me) 2014-04-20
US8232289B2 (en) 2012-07-31
UA107943C2 (xx) 2015-03-10
HK1169988A1 (en) 2013-02-15
MX2012005691A (es) 2012-06-13
IL219370A0 (en) 2012-06-28
TW201127841A (en) 2011-08-16
CA2796161C (en) 2015-03-17
CA2796161A1 (en) 2011-05-19
EA020848B1 (ru) 2015-02-27
CN102612520B (zh) 2015-04-08
HRP20130967T1 (hr) 2013-11-22
EA201290352A1 (ru) 2012-10-30
JP5680101B2 (ja) 2015-03-04
TWI465453B (zh) 2014-12-21
ZA201202967B (en) 2013-09-25

Similar Documents

Publication Publication Date Title
AR078863A1 (es) Derivados de espiropiperidina antagonista de receptores orl-1, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de la migrana, obesidad y/o depresion.
HRP20130969T1 (hr) Spojevi spiropiperidona kao antagonisti receptora orl-1
JP2013510859A5 (https=)
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
MX2009006751A (es) Compuestos agonistas y antagonistas del receptor de esfingosina-1-fosfato.
EA201590873A1 (ru) Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета2 адренергических рецепторов
PE20200016A1 (es) Imidazopirimidinas diazabiciclicas sustituidas y su uso para el tratamiento de trastornos respiratorios
CY1116328T1 (el) Παραγωγα 4 - αμινοπυριμιδινης και η χρηση τους ως ανταγωνιστων α2α υποδοχεων αδενοσινης
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
PE20150220A1 (es) Compuestos de tetrahidropirazolopirimidina
PE20151752A1 (es) Amidas heterociclicas como inhibidores de cinasas
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
JP2016509022A5 (https=)
EA201391662A1 (ru) Соединения с активностью антагонистов мускариновых рецепторов и агонистов адренергического рецептора бета2
AR091285A1 (es) Inhibidores de bromodominio y sus usos
CO2017008809A2 (es) Compuestos de benzoxaborol y uso de los mismos
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
PH12016500989A1 (en) Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonists
BRPI0606463A2 (pt) derivados triazol substituìdos com antagonistas de oxitocina
BRPI0809983A2 (pt) Quinolinas e seu uso terapêutico
EA201600435A1 (ru) Кристаллическая форма (s)-(2-(6-хлор-7-метил-1н-бензо[d]имидазол-2-ил)-2-метилпирролидин-1-ил)(5-метокси-2-(2h-1,2,3-триазол-2-ил)фенил)метанона и ее применение в качестве антагонистов орексинового рецептора
PE20142421A1 (es) Fenilimidazopirazoles sustituidos y su uso
AR072547A1 (es) 6- (1-piperazinil)-piridazinas sustituidas como antagonistas del receptor 5-ht6
AR076571A1 (es) Derivados de triazolopiridazinas y usos

Legal Events

Date Code Title Description
FG Grant, registration